Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts

Journal of Cellular Physiology

Volumn 227, Issue 9, 2012, Pages 3267-3277

  Suzuki, Hiroyuki ^a   Suda, Naoto ^a,b   Shiga, Momotoshi ^a   Kobayashi, Yukiho ^a   Nakamura, Masataka ^a   Iseki, Sachiko ^a   Moriyama, Keiji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ACROCEPHALOSYNDACTYLY; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE MUTATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PHOSPHORYLATION; PRIORITY JOURNAL;

ACROCEPHALOSYNDACTYLIA; ALKALINE PHOSPHATASE; ANIMALS; CALCIFICATION, PHYSIOLOGIC; CALCIUM PHOSPHATES; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CRANIOSYNOSTOSES; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MAP KINASE KINASE KINASE 3; MAP KINASE KINASE KINASES; MICE; MICE, TRANSGENIC; MUTATION; OSTEOGENESIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SIGNAL TRANSDUCTION; SKULL;

MUS; MUS MUSCULUS;

EID: 84858966906     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24021     Document Type: Article

References (53)

1. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7: 1475-1483.
2. Banerjee C, McCabe LR, Choi J, Hiebert SW, Stein JL, Stein GS, Lian JB. 1997. Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem 66: 1-8.
3. Cao YX, Jean JC, Williams MC. 2000. Cytosine methylation of an Sp1 site contributes to organ-specific and cell-specific regulation of expression of the lung epithelial gene t1α. Biochem J 350: 883-890.
4. Chen L, Li D, Li C, Engel A, Deng CX. 2003. A Ser252Trp substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33: 169-178.
5. Choi HJ, Nepal M, Park YR, Lee HK, Oh SR, Soh Y. 2011. Stimulation of chondrogenesis in ATDC5 chondroprogenitor cells and hypertrophy in mouse by Genkwadaphnin. Eur J Pharmacol 655: 9-15.
6. Cohen MM, Jr., Kreiborg S. 1996. Suture formation, premature sutural fusion, and suture default zones in Apert syndrome. Am J Med Genet 62: 339-344.
7. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, Marie PJ. 2001. Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 81: 68-81.
8. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
9. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
10. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632.
11. 2, interleukin-11, 9-cis retinoic acid and vitamin K2. Prostaglandins Leukot Essent Fatty Acids 65: 215-221.
12. Greenblatt MB, Shim JH, Zou W, Sitara D, Schweitzer M, Hu D, Lotinun S, Sano Y, Baron R, Park JM, Arthur S, Xie M, Schneider MD, Zhai B, Gygi S, Davis R, Glimcher LH. 2010. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 120: 2457-2473.
13. Guo X, Wang XF. 2009. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res 19: 71-88.
14. Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C. 2001. A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffersyndrome-like phenotypes. Proc Natl Acad Sci USA 98: 3855-3860.
15. Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C. 2009. Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328: 273-284.
16. Huang CY, Lee CY, Chen MY, Tsai HC, Hsu HC, Tang CH. 2010. Adiponectin increases BMP-2 expression in osteoblasts via AdipoR receptor signaling pathway. J Cell Physiol 224: 475-483.
17. Iseki S, Wilkie AO, Heath JK, Ishimaru T, Eto K, Morriss-Kay GM. 1997. Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124: 3375-3384.
18. Iseki S, Wilkie AO, Morriss-Kay GM. 1999. Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126: 5611-5620.
19. Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, Mao JI, Charnas LR, Jackson CE, Jaye M. 1994. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet 8: 275-279.
20. Kim HJ, Rice DP, Kettunen PJ, Thesleff I. 1998. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125: 1241-1251.
21. Kim HJ, Kim JH, Bae SC, Choi JY, Kim HJ, Ryoo HM. 2003. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 278: 319-326.
22. Kitagawa M, Tahara H, Kitagawa S, Oka H, Kudo Y, Sato S, Ogawa I, Miyaichi M, Takata T. 2006. Characterization of established cementoblast-like cell lines from human cementum-lining cells in vitro and in vivo. Bone 39: 1035-1042.
23. Kreiborg S, Cohen MM, Jr. 1990. Characteristics of the infant Apert skull and its subsequent development. J Craniofac Genet Dev Biol 10: 399-410.
24. Kreiborg S, Cohen MM, Jr. 1991. The infant Apert skull. Neurosurg Clin N Am 2: 551-554.
25. Mansukhani A, Bellosta P, Sahni M, Basilico C. 2000. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149: 1297-1308.
26. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C. 2005. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 168: 1065-1076.
27. Mantha M, Jumarie C. 2010. Cadmium-induced hormetic effect in differentiated Caco-2cells: ERK and p38 activation without cell proliferation stimulation. J Cell Physiol 224: 250-261.
28. Martínez-Abadías N, Percival C, Aldridge K, Hill CA, Ryan T, Sirivunnabood S, Wang Y, Jabs EW, Richtsmeier JT. 2010. Beyond the closed suture in Apert syndrome mouse models: Evidence of primary effects of FGFR2 signaling on facial shape at birth. Dev Dyn 239: 3058-3071.
29. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA. 1992. Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 89: 246-250.
30. Miraoui H, Marie PJ. 2010. Fibroblast growth factor receptor signaling crosstalk in skeletogenesis. Sci Signal 3: 1-5.
31. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. 2009. Fibroblast growth factor receptor 2 promotes osteognic differentiation in mesenchymal cells via extracellular-related kinase and protein kinase C signaling. J Biol Chem 284: 4897-4904.
32. Moenning A, Jäger R, Egert A, Kress W, Wardelmann E, Schorle H. 2009. Sustained platelet-derived growth factor receptor alpha signaling in osteoblasts results in craniosynostosis by overactivating the phospholipase C-gamma pathway. Mol Cell Biol 29: 881-891.
33. Montero JA, Gañan Y, Macias D, Rodriguez-Leon J, Sanz-Ezquerro JJ, Merino R, Chimal-Monroy J, Nieto MA, Hurle JM. 2001. Role of FGFs in the control of programmed cell death during limb development. Development 128: 2075-2084.
34. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2: 3005.1-3005.12.
35. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297.
36. Przylepa KA, Paznekas W, Zhang M, Golabi M, Bias W, Bamshad MJ, Carey JC, Hall BD, Stevenson R, Orlow S, Cohen MM, Jr., Jabs EW. 1996. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat Genet 13: 492-494.
37. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukani A. 2008. Osteoblast proliferation or differentiation is regulated by relative strength of opposing signaling pathways. J Cell Physiol 215: 442-451.
38. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S. 1994. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8: 98-103.
39. Rice DP, Åberg T, Chan YS, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Jr., Thesleff I. 2000. Integration of FGF and TWIST in calvarial bone and suture development. Development 127: 1845-1855.
40. Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, Jones B, Malcolm S, Winter RM, Oldridge M, Slaney SF, Poole MD, Wilkie AO. 1995. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes, Nat Genet 9: 173-176.
41. Saito M, Handa K, Kiyono T, Hattori S, Yokoi T, Tsubakimoto T, Harada H, Noguchi T, Toyoda M, Sato S, Teranaka T. 2005. Immortalization of cementoblast progenitor cells with Bmi-1 and TERT. J Bone Miner Res 20: 50-57.
42. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
43. Shiga M, Saito M, Hattori M, Torii C, Kosaki K, Kiyono T, Suda N. 2008. Characteristic phenotype of immortalized periodontal cells isolated from a Marfan syndrome type I patient. Cell Tissue Res 331: 461-472.
44. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. 2007. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39: 1145-1150.
45. Tang QQ, Otto TC, Lane MD. 2004. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA 101: 9607-9611.
46. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, Matsumoto T, Marie PJ, Moriyama K. 2004. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279: 45926-45934.
47. Vorlová S, Rocco G, Lefave CV, Jodelka FM, Hess K, Hastings ML, Henke E, Cartegni L. 2011. Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic PolyA activation. Mol Cell 43: 927-939.
48. +/S252W mouse. Development 132: 3537-3548.
49. Wang X, Goh CH, Li B. 2007. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology 148: 1629-1637.
50. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P. 1995. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9: 165-172.
51. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT. 2000. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 275: 4453-4459.
52. +/S252W mouse using a 3D hydrogel culture model. Bone 43: 55-63.
53. Yang L, Clinton JM, Blackburn ML, Zhang Q, Zou J, Zielinska-Kwiatkowska A, Tang BL, Chansky HA. 2008b. Rab23 regulates differentiation of ATDC5 chondroprogenitor cells. J Biol Chem 283: 10649-10657.